Grifols announces 23.8% increase in turnover

Grifols has published its financial results for the 2006 fiscal year, reporting a 23.8 per cent increase in turnover to 648 million euros (437.53 million pounds). Net profit rose 77.6 per cent on the previous year, reaching 45.4 million euros.

Bioscience at the firm, which amalgamates all activities related to the therapeutic use of plasma, grew by 21 per cent during the year to account for 68 per cent of the turnover of the company.

The hospital logistics division, concerned with non-biological pharmaceutical products for hospitals, grew by 19 per cent in 2006.

Grifols also noted the acquisition of 14 plasmapheresis centres, with a further eight purchased from Baxter in April as examples of the vertical integration of the company’s business and raw materials supply, with the firm becoming the second-largest plasma collection firm worldwide.

“The increase in sales of plasma derivatives – mainly in the United States – and the improvement in prices for some plasma derivatives such as albumin, Factor VII and intravenous immunoglobulin, were the driving force behind the group’s rising turnover,” the company reports.

Last May, Grifols announced a donation of haemophilia blood clotting therapies worth $1.4 million (0.72 million pounds) to the World Federation of Haemophilia.